Anne Bartu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne Bartu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Geoff S. Gawthorne
Epidemiology Branch, Department of Health, East Perth, Western Australia
2 shared publicationsKenneth F. Ilett
Clinical Pharmacology & Toxicology Laboratory, Path West Laboratory Medicine, Nedlands, Western Australia and
2 shared publicationsNerelie C. Freeman
Drug and Alcohol Office, Mt Lawley, Western Australia
2 shared publicationsAllan J. Quigley
Next Step Specialist Drug and Alcohol Services, Perth, Western Australia
1 shared publicationAurora Popescu
Next Step Specialist Drug and Alcohol Services, Western Australia
1 shared publicationC. D'Arcy J. Holman
1 shared publication
Latest Publications
- 18 September 2009
- Published by Taylor & Francis in Mental Health and Substance Use
- Vol. 2 (3) , 169-172
Are the terms dual diagnosis and comorbidity redundant?
- 18 September 2009
- Published by Taylor & Francis in Mental Health and Substance Use
- Vol. 2 (3) , 169-172
Are the terms dual diagnosis and comorbidity redundant?
- Open Access
- 1 April 2009
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 67 (4) , 455-459
Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The extent of drug transfer into milk during recreational intravenous use of methylamphetamine has not previously been studied. WHAT THIS STUDY ADDS • We have shown that methylamphetamine transfers into breast milk.• The amount a breastfed infant would receive varied over 2.5‐fold range.• A 48‐h withholding period for breastfeeding is recommended following recreational use.AIMS To investigate the transfer of amphetamines into breast milk following their recreational use and estimate drug exposure for the breastfed infant.METHODS Two breastfeeding mothers who were occasional recreational users of intravenous amphetamines were studied. A urine sample was collected 4 h after dose, and milk samples were collected over 24 h. Drug in urine was qualitatively identified by gas chromatography‐mass spectrometry and quantification in milk was by high‐performance liquid chromatography. Absolute infant dose via milk was estimated.RESULTS The urines contained predominantly methylamphetamine together with smaller amounts of amphetamine. In the 24 h after dose, average concentrations in milk were 111 µg l−1 and 281 µg l−1 for methylamphetamine and 4 µg l−1 and 15 µg l−1 for amphetamine in cases 1 and 2, respectively. Absolute infant doses for methylamphetamine plus amphetamine (as methylamphetamine equivalents) were 17.5 µg kg−1 day−1 and 44.7 µg kg−1 day−1, respectively, for cases 1 and 2.CONCLUSION These limited data suggest that breastfeeding should be withheld for 48 h after recreational amphetamine use.
- 1 April 2009
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 67 (4) , 455-459
Open AccessTransfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The extent of drug transfer into milk during recreational intravenous use of methylamphetamine has not previously been studied. WHAT THIS STUDY ADDS • We have shown that methylamphetamine transfers into breast milk.• The amount a breastfed infant would receive varied over 2.5‐fold range.• A 48‐h withholding period for breastfeeding is recommended following recreational use.AIMS To investigate the transfer of amphetamines into breast milk following their recreational use and estimate drug exposure for the breastfed infant.METHODS Two breastfeeding mothers who were occasional recreational users of intravenous amphetamines were studied. A urine sample was collected 4 h after dose, and milk samples were collected over 24 h. Drug in urine was qualitatively identified by gas chromatography‐mass spectrometry and quantification in milk was by high‐performance liquid chromatography. Absolute infant dose via milk was estimated.RESULTS The urines contained predominantly methylamphetamine together with smaller amounts of amphetamine. In the 24 h after dose, average concentrations in milk were 111 µg l−1 and 281 µg l−1 for methylamphetamine and 4 µg l−1 and 15 µg l−1 for amphetamine in cases 1 and 2, respectively. Absolute infant doses for methylamphetamine plus amphetamine (as methylamphetamine equivalents) were 17.5 µg kg−1 day−1 and 44.7 µg kg−1 day−1, respectively, for cases 1 and 2.CONCLUSION These limited data suggest that breastfeeding should be withheld for 48 h after recreational amphetamine use.
Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia
Aims This study compares the hazard of death among opiate and amphetamine using clients who accessed drug treatment with individuals who had no specialist treatment contact between 1985 and 1998.Design, setting, participants This was a retrospective cohort study of 4280 drug‐using individuals (2887 opiate users, 1393 amphetamine users) admitted to Perth metropolitan hospitals or Perth psychiatric institutions between 1985 and 1998. Of these, 1469 attended Next Step Specialist Drug and Alcohol Services (928 received methadone and 541 attended counselling or support groups) and 2811 had no contact with this service.Methods Data from two drug treatment programmes were linked with hospital morbidity, psychiatric services and the mortality database using record linkage.Findings The results show that people who were currently in drug treatment had a lower hazard of death compared with non‐clients and those who had ceased treatment. Those who had ceased treatment more than 6 months ago had 7.0 times the hazard of all‐cause death and 8.4 times the hazard of drug‐cause death. Opiate users were at 1.4 times the hazard of all‐cause death and 2.4 times the hazard of drug‐cause death compared with amphetamine users. Males were at 1.79 times the hazard of all‐cause death and, unexpectedly, were found to be at 2.69 times the hazard of drug‐cause death compared with females.Conclusions Treatment protected clients from premature death compared with people who did not receive treatment and also those who ceased treatment. While amphetamine users had a lower risk of mortality compared with opiate users, the full extent of the relationship between amphetamine use and mortality needs to be examined further.
Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia
Aims This study compares the hazard of death among opiate and amphetamine using clients who accessed drug treatment with individuals who had no specialist treatment contact between 1985 and 1998.Design, setting, participants This was a retrospective cohort study of 4280 drug‐using individuals (2887 opiate users, 1393 amphetamine users) admitted to Perth metropolitan hospitals or Perth psychiatric institutions between 1985 and 1998. Of these, 1469 attended Next Step Specialist Drug and Alcohol Services (928 received methadone and 541 attended counselling or support groups) and 2811 had no contact with this service.Methods Data from two drug treatment programmes were linked with hospital morbidity, psychiatric services and the mortality database using record linkage.Findings The results show that people who were currently in drug treatment had a lower hazard of death compared with non‐clients and those who had ceased treatment. Those who had ceased treatment more than 6 months ago had 7.0 times the hazard of all‐cause death and 8.4 times the hazard of drug‐cause death. Opiate users were at 1.4 times the hazard of all‐cause death and 2.4 times the hazard of drug‐cause death compared with amphetamine users. Males were at 1.79 times the hazard of all‐cause death and, unexpectedly, were found to be at 2.69 times the hazard of drug‐cause death compared with females.Conclusions Treatment protected clients from premature death compared with people who did not receive treatment and also those who ceased treatment. While amphetamine users had a lower risk of mortality compared with opiate users, the full extent of the relationship between amphetamine use and mortality needs to be examined further.
- 1 September 2003
- Published by Taylor & Francis in Journal of Substance Use
- Vol. 8 (3) , 150-154
Psychiatric comorbidity in a cohort of heroin and amphetamine users in Perth, Western Australia
- 1 September 2003
- Published by Taylor & Francis in Journal of Substance Use
- Vol. 8 (3) , 150-154
Psychiatric comorbidity in a cohort of heroin and amphetamine users in Perth, Western Australia
- 1 December 2002
- Published by Wiley in Drug and Alcohol Review
- Vol. 21 (4) , 335-340
Characteristics, retention and readmissions of opioid‐dependent clients treated with oral naltrexone
The aims of this study were to examine the retention rates of opioid‐dependent clients treated with oral naltrexone and identify factors that influence retention in treatment of 981 opioid‐dependent clients at a public out‐patient clinic in Perth, Western Australia. The average retention period for all clients was 9.0 weeks. The factors associated with longer retention were being employed and referral source. Clients who were employed stayed significantly longer in treatment than unemployed clients. Clients referred from a private clinic were retained in treatment significantly longer than those referred from other sources (X̄ = 10.3 vs. 5.9 weeks). While the majority (80.8%) had one admission to naltrexone treatment, 19.2% presented for readmission, some on three or more occasions in the study period. The median period between the end of the first episode of treatment and commencement of the second was 15.6 weeks. The median period between the end of the second episode of treatment and commencement of the third was 11.4 weeks. Those employed had a higher probability of being retained longer in treatment than those who were unemployed in subsequent treatment episodes. Clinicians should expect that initial retention in naltrexone is likely to be relatively short, and that a substantial proportion of clients will represent for further treatment.
- 1 December 2002
- Published by Wiley in Drug and Alcohol Review
- Vol. 21 (4) , 335-340
Characteristics, retention and readmissions of opioid‐dependent clients treated with oral naltrexone
The aims of this study were to examine the retention rates of opioid‐dependent clients treated with oral naltrexone and identify factors that influence retention in treatment of 981 opioid‐dependent clients at a public out‐patient clinic in Perth, Western Australia. The average retention period for all clients was 9.0 weeks. The factors associated with longer retention were being employed and referral source. Clients who were employed stayed significantly longer in treatment than unemployed clients. Clients referred from a private clinic were retained in treatment significantly longer than those referred from other sources (X̄ = 10.3 vs. 5.9 weeks). While the majority (80.8%) had one admission to naltrexone treatment, 19.2% presented for readmission, some on three or more occasions in the study period. The median period between the end of the first episode of treatment and commencement of the second was 15.6 weeks. The median period between the end of the second episode of treatment and commencement of the third was 11.4 weeks. Those employed had a higher probability of being retained longer in treatment than those who were unemployed in subsequent treatment episodes. Clinicians should expect that initial retention in naltrexone is likely to be relatively short, and that a substantial proportion of clients will represent for further treatment.
- 1 August 2002
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 26 (4) , 364-370
Methadone‐related deaths in Western Australia 1993–99
- 1 August 2002
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 26 (4) , 364-370
Methadone‐related deaths in Western Australia 1993–99